Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.710
-0.050 (-2.84%)
At close: Oct 8, 2025, 4:00 PM EDT
1.730
+0.020 (1.17%)
After-hours: Oct 8, 2025, 7:59 PM EDT
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
5.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.11M | -9.18M | -74.67% |
| Dec 31, 2021 | 12.29M | 7.98M | 185.26% |
| Dec 31, 2020 | 4.31M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
APVO News
- 13 hours ago - Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter - Accesswire
- 22 days ago - Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML - Accesswire
- 4 weeks ago - Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules - Accesswire
- 2 months ago - Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - Accesswire
- 2 months ago - Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - Accesswire
- 3 months ago - Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 3 months ago - Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers - Accesswire
- 3 months ago - Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga